Sakamoto Kotaro, Adachi Yusuke, Komoike Yusaku, Kamada Yusuke, Koyama Ryokichi, Fukuda Yasunori, Kadotani Akito, Asami Taiji, Sakamoto Jun-Ichi
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Biochem Biophys Res Commun. 2017 Jan 29;483(1):183-190. doi: 10.1016/j.bbrc.2016.12.170. Epub 2016 Dec 27.
Dedicator of cytokinesis 2 (DOCK2) is a key molecule for lymphocyte activation and migration. DOCK2 interacts with Ras-related C3 botulinus toxin substrate 1 (Rac1, GTPase) and mediates the GDP-GTP exchange reaction, indicating that inhibitors against protein-protein interaction (PPI) between DOCK2 and Rac1 would be good drug candidates for treating immune-related disorders. Here, we report DOCK2-selective PPI inhibitory peptides discovered using random peptide T7 phage display technology. These peptides inhibited DOCK2 activity at nanomolar concentrations and were delivered to intracellular compartments by combination with cell-penetrating peptide (CPP). Consequently, one peptide, R4-DCpep-2(V2W/K4R/ox)-NH (Ac-RRRRCWARYHGYPWCRRRR-NH), inhibited migration in human B lymphocyte MINO cell line at IC = 120 nM. To our knowledge, this is the first report of a DOCK2-selective peptide inhibitor; this study will contribute to the development of novel DOCK2-targeting immunosuppressive drugs.
细胞分裂素2(DOCK2)是淋巴细胞活化和迁移的关键分子。DOCK2与Ras相关的C3肉毒杆菌毒素底物1(Rac1,一种GTP酶)相互作用并介导GDP-GTP交换反应,这表明针对DOCK2与Rac1之间蛋白质-蛋白质相互作用(PPI)的抑制剂有望成为治疗免疫相关疾病的良好候选药物。在此,我们报告了利用随机肽T7噬菌体展示技术发现的DOCK2选择性PPI抑制肽。这些肽在纳摩尔浓度下就能抑制DOCK2活性,并通过与细胞穿透肽(CPP)结合被递送至细胞内区室。因此,一种名为R4-DCpep-2(V2W/K4R/ox)-NH(Ac-RRRRCWARYHGYPWCRRRR-NH)的肽在IC = 120 nM时可抑制人B淋巴细胞MINO细胞系的迁移。据我们所知,这是关于DOCK2选择性肽抑制剂的首次报道;本研究将有助于开发新型靶向DOCK2的免疫抑制药物。